Med BioGene (MBI) has received an offer from Signal Genetics and its subsidiary Respira Health to enter into a commercialization, license and research reimbursement agreement that would provide Respira with exclusive global rights to develop and commercialize MBI's test, LungExpress Dx.
LungExpress Dx is a 15-gene signature panel used for identifying patients with early-stage non-small-cell lung cancer who, following surgical removal of their tumor, are at a higher and lower risk of mortality.
On 1 March 2011, MBI had entered into a commercialization, license and research reimbursement agreement with Precision that would provide Precision with exclusive global rights to develop and commercialize LungExpress Dx.
MBI said that its board of directors are considering, in light of its obligations under its agreement with Precision, the offer from Signal and Respira and will announce its decision as to acceptance or rejection of such offer once a determination has been made.